The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:
- Erythromycin – Updated warnings regarding cardiovascular risks and infantile hypertrophic pyloric stenosis
- Vascular Endothelial Growth Factor (VEGF) pathway inhibitors – Risk of aneurysm and artery dissection
- Implanon NXT (etonogestrel implant) – Updated insertion and removal instructions due to risk of neurovascular injury and implant migration
- Insulin-containing medicines – Risk of cutaneous amyloidosis and potential for associated changes in glycaemic control
- Leuprorelin-containing depot medicines – Risk of lack of efficacy due to incorrect reconstitution and administration
- Xeljanz ▼(tofacitinib) – Updated recommendations due to increased risk of venous thromboembolism and serious and fatal infections
- Risk of respiratory depression and sedation associated with Epaclob 1mg/ml and 2mg/ml oral suspension (clobazam)